Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest CF101 Stories

2014-03-03 08:30:54

PETACH TIKVA, Israel, March 3, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program. The need to bring Dr. Simon on board...

2014-02-11 08:31:33

Company's Proprietary Drug CF101 Well-Positioned to Benefit from a Global RA Drug Market Study Forecasted to Generate Revenues of $38.5 bn in 2017 PETACH TIKVA, Israel, Feb. 11, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today commented on the overall growth of the global rheumatoid arthritis market opportunity and the...

2013-12-31 08:22:44

PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma...

2013-12-30 00:20:21

PETACH TIKVA, Israel, Dec. 30, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine...

2013-12-23 08:26:06

PETACH TIKVA, Israel, Dec. 23, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist. The study entailed 2 arms, a placebo and a CF101 1...

2013-12-11 08:29:39

PETACH TIKVA, Israel, Dec. 11, 2013 /PRNewswire/ -- Can-Fite BioPharma (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address anti-inflammatory and cancer diseases, today issued a Letter to Shareholders. Dear Fellow Can-Fite Shareholders, 2013 has truly been a pivotal year for Can-Fite. We have achieved numerous clinical, corporate, and financial milestones. Before the end of the year, we expect to announce results...

2013-11-20 08:27:59

Company's CF101 was selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier PETACH TIKVA, Israel, Nov. 20, 2013 /PRNewswire/ -- Can-Fite BioPharma (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address anti-inflammatory and cancer diseases, has just completed delivering a scientific presentation at Elsevier's 2013 Therapeutic Area Partnerships conference, where it is has...

2013-11-05 12:29:23

PETACH TIKVA, Israel, Nov. 5, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc.(OTCQB: OPLI), jointly announced today that the U.S. Patent and Trademark Office granted a U.S. patent which bears the Patent No. 8,557,790 and is titled "A3 Adenosine receptor agonists for the reduction of intraocular pressure"....

2013-09-03 16:27:48

PETACH TIKVA, Israel, Sept. 3, 2013 /PRNewswire/ -- OphthaliX Inc. (OTC BB: OPLID), announced today that the European Patent Office issued a Certificate of Grant of Patent for European Patent No. 1778239 entitled "Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren's syndrome". This patent was granted to OphthaliX's parent and majority stockholder, Can-Fite BioPharma Ltd., and relates to OphthaliX's drug candidate CF101. Pursuant to the license...

2013-07-16 20:21:28

PETACH TIKVA, Israel, July 16, 2013 /PRNewswire/ -- OphthaliX Inc. (OTC BB: OPLI), announced today the submission of a Phase II study protocol of its drug candidate, CF101, for the treatment of uveitis. The Phase II study will be conducted in Europe and Israel and will investigate the efficacy and safety of CF101 in 45 patients with active, sight-threatening, noninfectious intermediate or posterior uveitis, who will be treated with either CF101 or a placebo for a period of six...